HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•Radiology Business
FDA Clears Median's Eyonis AI for CT Lung Cancer Screening
Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
•AuntMinnie
Deep Learning Super-Resolution Boosts Accuracy of Coronary CT Angiography
Super-resolution deep learning reconstruction (SR-DLR) outperforms hybrid iterative reconstruction in coronary CT angiography for stenosis assessment.
•AuntMinnie
Task-Specific NLP Outperforms General LLMs for Lung Nodule Detection in Chest CT Reports
A radiology-trained NLP model significantly outperformed several general-purpose large language models in extracting incidental lung nodule data from chest CT reports.